Home/Pipeline/PCSK9 Multiplex Program

PCSK9 Multiplex Program

Cardiometabolic Disease

ResearchActive

Key Facts

Indication

Cardiometabolic Disease

Phase

Research

Status

Active

Company

nChroma Bio

About nChroma Bio

nChroma Bio is a private, preclinical-stage biotech founded in 2020 and headquartered in Boston, MA, USA. The company is pioneering a disease-first approach to genetic medicine, integrating epigenetic and gene-editing cargoes with a modular delivery platform (LNPs for liver, eVLPs for extrahepatic tissues) to create durable, targeted therapies. Its pipeline includes a Phase 1/2 candidate for chronic HBV and earlier research programs in cardiometabolic and CNS diseases, positioning it to address significant unmet needs in both hepatic and non-liver indications.

View full company profile

Therapeutic Areas

Infectious Disease Cardiometabolic Central Nervous System

Other Cardiometabolic Disease Drugs

Drug	Company	Phase	Status
PCSK9 Program	nChroma Bio	Candidate-Enabled	Active
Undisclosed Peripheral	Manifold Bio	Pre-clinical	Active
Undisclosed (Cardiometabolic)	SanegeneBio	Phase 1	Active